Thank you for claiming your business. Kindly check your Email for verification mail from Sulekha.com Our team will contact you shortly!.
About Halozyme, Inc
We are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor micro environment. Our lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. By breaking down potential barriers to cancer, PEGPH20 may help make existing treatments more effective allowing therapies to reach the tumor. We are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, Roche, Pfizer, Janssen, Baxalta, AbbVie and Lilly, for our ENHANZE™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. This technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously.
